Literature DB >> 18050128

Retinal angiomatous proliferation reactivation 6 months after high-dose intravitreal acetonide triamcinolone and photodynamic therapy.

J Reche-Frutos1, C Calvo-Gonzalez, J Donate-Lopez, J Garcia-Feijoo, F Saenz-Frances, C Fernandez-Perez, J Garcia-Sanchez.   

Abstract

PURPOSE: To describe the incidence of retinal angiomatous proliferation (RAP) reactivation after combined treatment with a high-dose intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) at 1-year follow-up.
METHODS: All patients had undergone a full ophthalmic examination. High-dose IVTA (20 mg) was injected via pars plana. Four to 7 days later, PDT was delivered.
RESULTS: Fourteen eyes of 13 patients were included. Eight lesions (57%) reopened and needed retreatment with combined therapy at 6 months follow-up. At 1-year follow up, the lesion was obliterated in nine cases (64.2%) and best-corrected visual acuity improved from 0.87 logMar (range, 0.7-1) to 0.79 logMar (range, 0.5-1).
CONCLUSIONS: Combined therapy using high-dose IVTA and PDT is beneficial in stabilizing RAP. However, a high incidence of RAP reactivation has been observed at 6 months, even with a high-dose IVTA injection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18050128     DOI: 10.1177/112067210701700619

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  4 in total

1.  Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Authors:  Ebenezer Daniel; James Shaffer; Gui-shuang Ying; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Maureen G Maguire
Journal:  Ophthalmology       Date:  2015-12-08       Impact factor: 12.079

2.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

3.  Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Authors:  Lazaros Konstantinidis; Evangelia Mameletzi; Irmela Mantel; Jean-Antoine Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-29       Impact factor: 3.117

4.  Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation.

Authors:  Saya Nakano; Shigeru Honda; Hideyasu Oh; Mihori Kita; Akira Negi
Journal:  Clin Ophthalmol       Date:  2012-02-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.